Precipio stock analysis
Precipio (TGK) Stock Price & Analysis
TGK Stock Chart & Stats
- Day’s Range
- EUR 5.90 - EUR 5.90
- 52-Week Range
- EUR 5.90 - EUR 5.90
- Previous Close
- EUR 5.90
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 38.15M
- Enterprise Value
- EUR 42.52M
- Total Cash (Recent Filing)
- EUR 3.58M
- Total Debt (Recent Filing)
- EUR 3.69M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Apr 05, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Expansion
The sustained increase in revenue shows that Precipio is expanding its commercial base across pathology and products. Continued growth from 2021 through the latest TTM period provides a stronger foundation for operating leverage, customer adoption, and future cash generation.
Positive Cash Flow And Modest Leverage
Positive operating and free cash flow improve financial self-sufficiency and reduce dependence on external financing. Combined with modest leverage, this gives Precipio greater flexibility to fund commercial expansion and absorb execution variability while scaling its laboratory and product businesses.
Scalable Commercial And Operating Infrastructure
Infrastructure capacity well above current revenue creates room for growth without a proportional increase in core facilities and equipment spending. If customer acquisition improves, this operating platform could support greater volume and allow incremental revenue to translate more effectively into margins.
Bears Say
Profitability Has Not Yet Been Achieved
Despite revenue and cash-flow improvement, persistent net and operating losses show that the business has not yet demonstrated durable earnings power. Negative returns on equity also indicate that the current capital base is not producing attractive profits, leaving execution dependent on further scale and efficiency gains.
Growth Is Below Management Expectations
Slower product and pathology growth could delay the revenue scale needed to achieve management’s longer-term targets. It also raises execution risk because future expansion depends on improving commercial productivity, winning new customers, and restoring momentum in both operating divisions.
Long Customer Onboarding Delays Revenue Conversion
Long and variable onboarding cycles make the timing of revenue conversion difficult to predict and can extend the payback period on sales investment. They may also cause a lag between pipeline growth and reported results, increasing the risk that near-term commercial hiring produces revenue only much later.
TGK FAQ
What was Precipio’s price range in the past 12 months?
What is Precipio’s market cap?
When is Precipio’s upcoming earnings report date?
How were Precipio’s earnings last quarter?
Is Precipio overvalued?
Does Precipio pay dividends?
What is Precipio’s EPS estimate?
How many shares outstanding does Precipio have?
What happened to Precipio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Precipio?
What is the TipRanks Smart Score and how is it calculated?
Precipio Stock Smart Score
Company Description
Precipio
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ilan Danieli
- Employees
- 61
- Website
- www.precipiodx.com
- Address
- 4 Science Park, New Haven, CT, 06511, US
Precipio (TGK) Earnings & Revenues
TGK Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Management highlighted cash-flow positivity, a cash balance above $3.5 million, the first quarter with product revenue above $1 million, established distribution and commercial infrastructure, and ambitious 2027 revenue targets. The main challenges were that product growth remains below management's expectations, pathology growth has slowed, and customer onboarding and sales-representative ramp times are long. Management nevertheless expressed confidence in its pipeline and its ability to accelerate growth.
View all DE:TGK earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 2 |
| Technical Analysis | 0 | 1 | 0 |
| Moving Averages | 6 | 4 | 2 |












